Prahlad Singh
Also at Revvity Inc
About
Prahlad Singh is the 60-year-old President and Chief Executive Officer of Revvity, having assumed the role on December 30, 2019.
He began his tenure at Revvity in May 2014 as the President of the Diagnostics business. Over the years, he has advanced through significant leadership roles, including promotions to Senior Vice President in September 2016, Executive Vice President in March 2018, and later to President and Chief Operating Officer in January 2019 before his current appointment.
Academically, he holds a doctoral degree in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University. Prior to joining Revvity, he built an impressive career by holding senior executive roles in companies such as GE Healthcare, Philips Healthcare, DuPont Pharmaceuticals, and Bristol-Myers Squibb Medical Imaging, contributing to strategic initiatives and operational excellence in the healthcare sector.
$RVTY Performance Under Prahlad Singh
Past Roles
Organization | Role | Date Range | Details |
---|---|---|---|
Revvity (RVTY) | President and Chief Operating Officer | Jan 2019 - Dec 2019 | Served prior to being elected CEO on Dec 30, 2019 |
Revvity (RVTY) | Executive Vice President | Mar 2018 - Jan 2019 | Promoted from Senior VP |
Revvity (RVTY) | Senior Vice President | Sep 2016 - Mar 2018 | |
Revvity (RVTY) | President of the Diagnostics Business | May 2014 - Sep 2016 | Joined RVTY in May 2014 leading the Diagnostics business |
GE Healthcare | General Manager, Women’s Health Business | 2012 - 2014 | Oversaw mammography and bone densitometry businesses; held senior executive roles in strategy, business development and M&A |
Philips Healthcare | Senior Executive (Strategy, Business Development & M&A) | N/A | |
DuPont Pharmaceuticals | Leadership Roles | N/A | Held roles of increasing responsibility |
Bristol-Myers Squibb Medical Imaging | Regional Manager (Asia Pacific & Middle East) | N/A | Managed the Asia Pacific and Middle East region |
External Roles
Organization | Role | Date Range | Details |
---|---|---|---|
Amphenol Corporation | Board Member | N/A | Publicly traded |
Analytical, Life Sciences & Diagnostics Association (ALDA) | Board Member | N/A | |
Massachusetts General Hospital | Member, President’s Council | N/A |
Fixed Compensation
Component Name | Amount ($) | Payment Schedule | Additional Details |
---|---|---|---|
Base Salary | 1,086,539 | N/A | Fixed yearly salary |
401(k) Company Match | 15,250 | N/A | Included in All Other Compensation |
Executive Health Program | 2,227 | N/A | Included in All Other Compensation |
Life Insurance Premiums | 15,000 | N/A | Included in All Other Compensation |
Performance Compensation
Performance Metrics
Metric | Weight (%) | Threshold | Target | Maximum | Actual Result |
---|---|---|---|---|---|
Non-COVID Organic Revenue | 40 | 7.0% | 9.0% | 12.0% | 2.0% (0% achievement) |
Adjusted EPS | 40 | $4.85 | $5.15 | $5.55 | $4.78 (0% achievement) |
Free Cash Flow Conversion | 20 | 70% | 80-85% | 100% | 77% (85% achievement) |
Award Breakdown
- Target Award Opportunity: $1,485,000 (135% of base salary)
- Approved Award: $315,563 (21% of the target award)
- Evaluation Period: Full fiscal year 2023
- Vesting Schedule: Not applicable – cash incentive
- Grant Date / Stock Price: Not applicable as it is not an equity-based award